Enterprise Value

24.22B

Cash

3.18B

Avg Qtr Burn

N/A

Short % of Float

2.64%

Insider Ownership

0.00%

Institutional Own.

60.76%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYVGART Hytrulo (Efgartigimod) Details
Chronic inflammatory disorder

Approved

Quarterly sales

VYVGART Hytrulo (SC Efgartigimod) Details
Autoimmune disease, Myasthenia gravis

Approved

Quarterly sales

Efgartigimod Details
Primary immune thrombocytopenia

Phase 3

Update

Efgartigimod Details
Sjögren-Larsson Syndrome

Phase 3

Initiation

Efgartigimod Details
Dermatomyositis , Anti-synthetase syndrome, Immune-mediated necrotizing myopathy

Phase 2/3

Data readout

Empasiprubart Details
Neuropathy, Neuromuscular disease, Multifocal motorneuropathy

Phase 2

Data readout

Efgartigimod Details
Post-COVID Postural Orthostatic Tachycardia Syndrome

Phase 2

Data readout

Empasiprubart Details
Dermatomyositis

Phase 2

Initiation

Empasiprubart Details
Delayed graft function

Phase 2

Initiation

ARGX -119 Details
Amyotrophic lateral sclerosis, Congenital myasthenic syndrome

Phase 1

Data readout

Efgartigimod Details
Mucosal Pemphigus Vulgaris

Failed

Discontinued